Ladd Family Pharmacy LLC, Boise, ID
Is Ladd Family Pharmacy LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Ladd Family Pharmacy LLC hold a Idaho pharmacy license?
State board of pharmacy records for Idaho are not checked: the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read. The Colorado State Board of Pharmacy also lists nonresident license OSP 6664 for Ladd Family Pharmacy LLC, Boise, ID, status Expired, as of Nov 15, 2026.
Has Ladd Family Pharmacy LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Apr 9, 2020), 1 state referral letter (Apr 9, 2020) and 1 FMD-145 letter (Apr 9, 2020) for Ladd Family Pharmacy LLC. State board of pharmacy records for Idaho are not checked: the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Ladd Family Pharmacy LLC
- Location
- Boise, ID
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 9, 2020
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 6 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Ladd Family Pharmacy LLC, a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Apr 9, 2020 | State referral letter | State Referral Letter Issued 04/09/2020 | Not linked by FDA |
| Apr 9, 2020 | Warning letter close-out | Warning Letter Close Out Issued 04/09/2020 | Not linked by FDA |
| Apr 9, 2020 | FMD-145 letter | FMD-145 Letter Issued 04/09/2020 | Not linked by FDA |
| Jul 30, 2019 | Form 483 | 483 Issued 07/30/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Ladd Family Pharmacy LLC, Boise, ID (FEI number 3012773475), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 30, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012773475 | 1098776 |
| Sep 23, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012773475 | 987553 |
Form 483s FDA has published for this site
- Jul 30, 2019: Form 483 to Ladd Family Pharmacy LLC, published Sep 30, 2019. fda.gov
- Oct 17, 2016: Form 483 to Ladd Family Pharmacy LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 6 numbered observations in all, across 2 inspections ending Sep 23, 2016 to Jul 30, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 22, 2019 to Jul 30, 2019: 2 observations
- Firm on the cover
- Ladd Family Pharmacy LLC, 1109 S Broadway Ave, Boise, ID 83706-3626
- FEI number
- 3012773475
- Establishment type on the cover
- Producer of Nonsterile Drug Products
- FDA district office on the cover
- 22215 26t h Ave SE Suite 210 Bothell, WA 98021
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You used a non-phaimaceutical grade component in the formulations of a drug product.
Specifically,
You have not demonstrated that the water used as a component of aqueous drug products meets the minimum requirements for USP Purified Water. For example, the <Redacted B4> water was used as a component for Acetaminophen [Free] 12mg/mL Liquid lot number 07102019:66@26.
Observation 2
You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically,
You failed adequately clean non-dedicated equipment. For example an oxidizing agent was not used to clean non-dedicated equipment following the compounding of a testosterone containing product.
Inspection Sep 12, 2016 to Sep 23, 2016: 4 observations
- Firm on the cover
- Ladd Family Pharmacy LLC, 1109 S Broadway Ave, Boise, ID 83706-3626
- Establishment type on the cover
- Manufacturer
- FDA district office on the cover
- Bothell, WA 98021
- Matched to this page by
- firm name, city and state on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
The firm has not implemented a stability program to scientifically determine appropriate expiration dates to assign to the manufacturing of non-sterile drug products, and does not assign expiration dates based on product-specific documented standards. For example, Bezocaine/Lidocaine/Tetracaine 20/10/4% gel, lot 08172016:84@2, manufactured for “REDACTED (b) (4)" per Rx REDACTED (b)(4), REDACTED (b)(6), was assigned a beyond-use date (BUD) of 30 days per a documented standard for all water-containing topical semisolid formulations. Cantharidin topical liquid 0.7% solution, lot 07262016:27@8, manufactured for REDACTED (b)(4) per Rx REDACTED (b)(4), REDACTED (b)(6) was assigned a BUD of 180 days per documented standard guidelines for all non -aqueous formulations. Both of these products were manufactured to fill non-patient specific prescriptions. ...
Observation 2
Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically,
The REDACTED (b)(4) hoods that are used to manufacture non-sterile drug products for human and veterinary use are not being cleaned in a manner that is effective in removing residues from previous manufactured products from joints and surfaces on the inside of the hoods. On 09/12/16, we observed that white powder residue was present in the welded joint between the work surface and back panel, and in the
Observation 3
The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.
Specifically,
The firm's SOP 1.30, version 3.0, titled "Compounding Area Requirements (Nonsterile)", states that garb may include “REDACTED (b)(4)" for employees working in the " Compounding Area", but does not define the areas to REDACTED (b)(4) to reduce the risk of product contamination. On 09/12/16, we observed an employee performing manufacturing of lot 09122016:31@7 of Estradiol (PGF) 1mg/gm Lipo and lot 09122016:98@18 of ltraconazole/buprofen 1/2% DMSO nail solution REDACTED (b)(4). We observed this employee exit the "Compounding Area" into the general pharmacy area and return to the "Compounding Area" without REDACTED (b)(4). The firm's SOP 1.30, version 3.0, titled "Compounding Area Requirements (Nonsterile)", states that garb may include “REDACTED (b)(4)" for employees working in the " Compounding Area", but does not define the areas to REDACTED (b)(4) to reduce the risk of product contamination. ...
Observation 4
Determinations of conformance to appropriate written specifica6ons for acceptance are not made and deficient for drug products.
Specifically,
Finished product testing is not performed on every lot of non-sterile manufactured drug product produced by the firm. The firm sends out REDACTED (b)(4) for potency testing by a contract laboratory every REDACTED (b)(4) or so, but does not have an established schedule or system for choosing which products to test. For example, the following non-sterile products were manufactured to fill multiple non-patient specific prescriptions between 06/12/16 and 09/ 12/16, none of which were tested prior to release:
Bezocaine/Lidocaine/Tetracaine 20110/4% gel, manufactured to fill REDACTED (b)(4) non-patient specific prescriptions between 06/ 12/16 and 09/ 12/16.
Cantharidin topical liquid 0. 7% solution, manufactured to fill REDACTED (b)(4) non-patient specific prescriptions between 06112/16 and 09/12/16. Cantharidin topical liquid 0. 7% solution, manufactured to fill REDACTED (b)(4) non-patient specific prescriptions between 06112/16 and 09/12/16. Cantharidin topical liquid 0. ...
State board of pharmacy records
State board of pharmacy records for Idaho are not checked: the board’s former web address (bop.idaho.gov) did not respond on November 6, 2026, and no longer resolved when tried again on November 7, 2026; the board’s pages now sit on the Division of Occupational and Professional Licenses site, which this index has not yet read.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6664 | OSP | Ladd Family Pharmacy LLC | Boise, ID | Expired |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.